Apolipoprotein E deficiency enhances the anti-tumor immunity via repressing T cell exhaustion

References

• Avila EM, Holdsworth G, Sasaki N, Jackson RL, Harmony JA. 1982. Apoprotein E suppresses phytohemagglutinin-activated phospholipid turnover in peripheral blood mononuclear cells. J Biol Chem. 257(10):5900–5909.
   Web of Science ®Google Scholar
• Azuma M, Kojimab T, Yokoyama I, et al. 2000. A synthetic peptide of human apoprotein E with antibacterial activity. Peptides. 21(3):327–330.
   Web of Science ®Google Scholar
• Bonacina F, Coe D, Wang G, Longhi MP, Baragetti A, Moregola A, Garlaschelli K, Uboldi P, Pellegatta F, Grigore L, et al. 2018. Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. Nat Commun. 9(1):3083.
   PubMedGoogle Scholar
• Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, et al. 2018. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 562(7728):605–609.
   PubMed Web of Science ®Google Scholar
• Domínguez-Soto A, de las Casas-Engel M, Bragado R, Medina-Echeverz J, Aragoneses-Fenoll L, Martín-Gayo E, van Rooijen N, Berraondo P, Toribio ML, Moro MA, et al. 2014. Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization. J Immunol. 193(10):5181–5189.
   Web of Science ®Google Scholar
• Drijvers JM, Sharpe AH, Haigis MC. 2020. The effects of age and systemic metabolism on anti-tumor T cell responses. Elife. 9:e62420.
   Web of Science ®Google Scholar
• Gaglione R, Pizzo E, Notomista E, de la Fuente-Nunez C, Arciello A. 2020. Host defence cryptides from human apolipoproteins: applications in medicinal chemistry. Curr Top Med Chem. 20(14):1324–1337.
   Web of Science ®Google Scholar
• Gui X, Deng M, Song H, Chen Y, Xie J, Li Z, He L, Huang F, Xu Y, Anami Y, et al. 2019. Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer Immunol Res. 7(8):1244–1257.
   PubMed Web of Science ®Google Scholar
• Huvila J, Brandt A, Rojas CR, Pasanen S, Talve L, Hirsimäki P, Fey V, Kytömäki L, Saukko P, Carpén O, et al. 2009. Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression In poorly differentiated tumors. Int J Gynecol Cancer. 19(7):1226–1231.
   Web of Science ®Google Scholar
• Jeong H, Hwang I, Kang SH, Shin HC, Kwon SY. 2019. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 22(1):38–51.
   PubMed Web of Science ®Google Scholar
• Kojima T, Fujimitsu Y, Kojima H. 2005. Anti-tumor activity of an antibiotic peptide derived from apoprotein E. In Vivo. 19(1):261–264.
   Web of Science ®Google Scholar
• Lee YS, Yeo IJ, Kim KC, Han SB, Hong JT. 2019. Inhibition of lung tumor development in ApoE knockout mice via enhancement of TREM-1 dependent NK cell cytotoxicity. Front Immunol. 10:1379.
   PubMed Web of Science ®Google Scholar
• Maezawa I, Nivison M, Montine KS, Maeda N, Montine TJ. 2006. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J. 20(6):797–799.
   Google Scholar
• Maimela NR, Liu S, Zhang Y. 2019. Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J. 17:1–13.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Locati M. 2005. Macrophage polarization comes of age. Immunity. 23(4):344–346.
   PubMed Web of Science ®Google Scholar
• Martins IJ, Hone E, Foster JK, Sünram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN. 2006. Apolipoprotein e, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry. 11(8):721–736.
   PubMed Web of Science ®Google Scholar
• McNeill E, Channon KM, Greaves DR. 2010. Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin Sci (Lond). 118(11):641–655.
   Web of Science ®Google Scholar
• Munhoz RR, Postow MA. 2016. Recent advances in understanding antitumor immunity. F1000Res. 5:2545.
   Google Scholar
• Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H, Yasui W. 2004. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res. 64(7):2397–2405.
   Web of Science ®Google Scholar
• Parisi L, Gini E, Baci D, Tremolati M, Fanuli M, Bassani B, Farronato G, Bruno A, Mortara L. 2018. Macrophage polarization in chronic inflammatory diseases: killers or builders? J Immunol Res. 2018:1–25.
   Web of Science ®Google Scholar
• Patil S, Rao RS, Majumdar B. 2015. T-cell exhaustion and cancer immunotherapy. J Int Oral Health. 7(8):i–ii.
   Google Scholar
• Phillips MC. 2014. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 66(9):616–623.
   PubMed Web of Science ®Google Scholar
• Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting In embryonic stem cells. Proc Natl Acad Sci U S A. 89(10):4471–4475.
   PubMed Web of Science ®Google Scholar
• Ringel AE, Drijvers JM, Baker GJ, Catozzi A, García-Cañaveras JC, Gassaway BM, Miller BC, Juneja VR, Nguyen TH, Joshi S, et al. 2020. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell. 183(7):1848–1866.e26.
   PubMed Web of Science ®Google Scholar
• Sharma N, Atolagbe OT, Ge Z, Allison JP. 2021. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 218(7):e20201811.
   Web of Science ®Google Scholar
• Su WP, Chen YT, Lai WW, Lin CC, Yan JJ, Su WC. 2011. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer. 71(1):28–33.
   PubMed Web of Science ®Google Scholar
• Suárez-Sánchez FJ, Lequerica-Fernández P, Suárez-Canto J, Rodrigo JP, Rodriguez-Santamarta T, Domínguez-Iglesias F, García-Pedrero JM, de Vicente JC. 2020. Macrophages in oral carcinomas: relationship with cancer stem cell markers and PD-L1 expression. Cancers (Basel). 12(7):1764.
   Web of Science ®Google Scholar
• Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, et al. 2018. LXR/ApoE activation restricts innate immune suppression in cancer. Cell. 172(4):825–840.e18.
   PubMed Web of Science ®Google Scholar
• Van Oosten M, Rensen PC, Van Amersfoort ES, Van Eck M, Van Dam AM, Brevé JJ, Vogel T, Panet A, Van Berkel TJ, Kuiper J. 2001. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality: a new therapeutic approach to treat gram-negative sepsis. J Biol Chem. 276(12):8820–8824.
   Web of Science ®Google Scholar
• Vitek MP, Snell J, Dawson H, Colton CA. 1997. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. Biochem Biophys Res Commun. 240(2):391–394.
   Web of Science ®Google Scholar
• Wherry EJ. 2011. T cell exhaustion. Nat Immunol. 12(6):492–499.
   PubMed Web of Science ®Google Scholar
• Zanfardino A, Bosso A, Gallo G, et al. 2018. Human apolipoprotein E as a reservoir of cryptic bioactive peptides: the case of ApoE 133-167. J Pept Sci. 24(7):e3095.
   Web of Science ®Google Scholar
• Zhang HL, Wu J, Zhu J. 2010. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Dev Immunol. 2010:186813.
   Google Scholar